Latest News
ZeniMax Media has closed a USD150m investment by private equity firm Providence Equity Partners in convertible preferred stock of the company.
The proceeds will be used to fund additional growth through increased game development, expanded publishing operations, and strategic acquisitions.
The new investment by Providence supplements an earlier investment of USD300m made by the firm in October 2007.
ZeniMax Media was founded in 1999 by Robert A. Altman, its chairman and chief executive, and through its wholly owned subsidiary, Bethesda Softworks, publishes interactive entertainment content for gaming consoles.
"Though a number of prominent private equity firms offered to invest with
Funds managed by Dutchess Capital have consummated USD210m in equity line facilities through the third quarter of 2010.
The financing transactions were completed with publicly traded companies listed in the US, Canada, UK and Australia.
Michael A. Novielli, Dutchess co-founder and managing partner, says: “We’ve been a market leader in ELF financings for over ten years having structured USD2bn in global transactions. Over the past decade we’ve seen the ELF grow in stature from relative obscurity due to the success that companies have had raising capital utilising this structure.
“Given the lingering effects of the global recession, traditional financing
GreensLedge Capital Markets has formed GreensLedge Asia, Tokyo Branch to expand the firm’s business activities in the Asian markets.
Iku Nishino has joined GreensLedge Asia as a managing director and general manager where he will be responsible for providing capital markets advisory solutions and managing transaction executions from the firm’s Tokyo office.
Nishino joins from J.P. Morgan Tokyo where he was a managing director and head of fixed income sales overseeing relationships with major institutional accounts.
"We have had great success providing specialised advisory and capital markets solutions to clients seeking unbiased, conflict-free advice," says Brian Zeitlin, managing partner of
Olympus Partners, a Connecticut-based private equity firm, has promoted several staff members to principal and vice president levels.
The following have been promoted to principal: Evan J. Eason, David M. Haddad, and Michael D. Horgan.
Vice president promotions have been given to Jason M. Miller and Sean P. Whiteley.
Olympus Partners focuses on companies in the business services, transportation and logistics services, healthcare manufacturing and services, financial services, consumer and restaurant and software and IT services sectors.
German law firm Schultze & Braun, a business recovery, insolvency and restructuring specialist, has opened its Paris office.
The Paris office is under the direction of Ellen Delzant and Patrick Ehret.
Working in close collaboration with the teams in Germany, the Paris team advises French clients on all matters pertaining to French, German and EU corporate law.
The firm established offices in London in 2006 and Strasbourg in 2007.
“The launch of the Paris office is an integral part of the firm’s development strategy, which entails getting closer to our French clients (businesses and banks), in order to assist them
UK private equity house Inflexion Private Equity has closed its new 2010 Buyout Fund which has raised a total of GBP375m.
Carey Olsen’s corporate group in Guernsey advised Inflexion on the establishment and regulation of the fund, as a closed-end registered collective investment scheme in the form of a dual limited partnership structure.
The firm also provided legal advice on corporate governance and administration.
The 2010 Buyout Fund will target high-growth UK companies and will look at ten to 15 potential investment opportunities. It is the first offshore fund to be established by Inflexion.
The Carey Olsen team was led
IS Pharma, a pharmaceutical company, has raised GBP3.6m through the issue of 4,613,160 new ordinary shares at 77 pence per placing share with Abingworth.
Following this placing, Abingworth will be IS Pharma’s largest shareholder with 13 per cent of the shares in issue.
The placing price at 77 pence represents a nine per cent premium to the closing price of 70.5 pence per ordinary share on 5 October 2010.
Tim Wright, chief executive of IS Pharma, says: “Abingworth has an excellent reputation as a strategic healthcare investor and we are delighted with their enthusiasm for investing in IS Pharma, as
Kana Software, a provider of software solutions for service experience management backed by Accel-KKR, has entered into a definite agreement to acquire Lagan Technologies, a provider of government to citizen technology.
Lagan is being sold by DFJ Esprit, which was the largest shareholder in the company.
The transaction will complement Kana’s capabilities in the communications, financial services, healthcare, retail and technology sectors.
The terms of the transaction were not disclosed.
Lagan software powers 200 government agencies worldwide at the national, regional and city level, serving 60 million citizens a year.
The combined entities will deliver rapid response to billions of
General Atlantic, a growth equity firm, has made a series of promotions to managing director and principal level.
The following have been promoted to managing director: Alexander A. Chulack, Cory A. Eaves and Brett B. Rochkind, all based in New York; Patricia L. Hedley, based in Greenwich, Connecticut; and Gabriel C. Caillaux, based in London.
The following individuals have been promoted to principal: Abhishek Agrawal and Robbert Vorhoff, both based in New York; and Nishant Sharma, based in Mumbai, India.
“These appointments reflect GA’s strong commitment to attracting, developing and promoting talented professionals globally,” says William E. Ford, chief executive
Third Rock Ventures, a venture capital firm focused on launching life sciences companies, has appointed Steven M. Paul as venture partner.
Paul is the former president of the Lilly Research Laboratories of Eli Lilly and now leads the Helen & Robert Appel Institute for Alzheimer’s Research at Weill Cornell Medical College.
As a venture partner, Paul will serve as a senior adviser to the firm and participate in the ideation and development of potential new companies.
"Steve brings invaluable experience to our team as we expand our company building efforts into new therapeutic areas, and we are delighted to welcome
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
